June 30 (Reuters) - Intellipharmaceutics International Inc IPCI.TO :
* Intellipharmaceutics announces FDA advisory committee meeting for rexista (oxycodone hydrochloride extended release), an abuse deterrent opioid analgesic for the treatment of moderate to severe pain
* Intellipharmaceutics International Inc - FDA set a target action date under prescription drug user fee act of September 25, 2017 Source text for Eikon: ID:nGNXNYSMDa Further company coverage: IPCI.TO